Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,956 questions in 143 reviews · Musculoskeletal
current versionsNo studies 555 · 28.4%Ungraded 107 · 5.5%Very low 255 · 13%Low 555 · 28.4%Moderate 357 · 18.3%High 127 · 6.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
High‐dose colchicine vs placebo Pain ‐ not reported · people with acute gout Colchicine for acute gout (2021) · Cochrane | no estimate extracted | NR | No studies |
High‐dose colchicine vs placebo Participant global assessment of treatment success: proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours · people with acute gout Colchicine for acute gout (2021) · Cochrane | RR 2.16 [1.28, 3.65] | 2 studies · 124 participants | Low |
Ultrasound‐guided injection vs non‐image‐guided injection Overall Pain numerical rating scale 0 to 10 points (lower score indicates less pain) · Patients with shoulder pain Image‐guided glucocorticoid injection versus injection without image guidance for shoulder pain (2021) · Cochrane | no estimate extracted | 15 studies · 1003 participants | Moderate |
Ultrasound‐guided injection vs non‐image‐guided injection Function various scales 0 to 100 points (higher score indicates better function) · Patients with shoulder pain Image‐guided glucocorticoid injection versus injection without image guidance for shoulder pain (2021) · Cochrane | no estimate extracted | 14 studies · 895 participants | Moderate |
Ultrasound‐guided injection vs non‐image‐guided injection Participant‐assessed success 50% improvement on numerical rating 0 to 10 scale for pain) · Patients with shoulder pain Image‐guided glucocorticoid injection versus injection without image guidance for shoulder pain (2021) · Cochrane | RR 1.56 [0.89, 2.75] | 5 studies · 350 participants | Very low |
Ultrasound‐guided injection vs non‐image‐guided injection Quality of life SF‐36 MCS 0 to 100 points (higher score indicates better quality of life) · Patients with shoulder pain Image‐guided glucocorticoid injection versus injection without image guidance for shoulder pain (2021) · Cochrane | no estimate extracted | 2 studies · 220 participants | Low |
Ultrasound‐guided injection vs non‐image‐guided injection Number of adverse events · Patients with shoulder pain Image‐guided glucocorticoid injection versus injection without image guidance for shoulder pain (2021) · Cochrane | RR 0.72 [0.4, 1.28] | 5 studies · 402 participants | Low |
Ultrasound‐guided injection vs non‐image‐guided injection Serious adverse events Not reported · Patients with shoulder pain Image‐guided glucocorticoid injection versus injection without image guidance for shoulder pain (2021) · Cochrane | no estimate extracted | NR | No studies |
Ultrasound‐guided injection vs non‐image‐guided injection Number of withdrawals due to adverse events · Patients with shoulder pain Image‐guided glucocorticoid injection versus injection without image guidance for shoulder pain (2021) · Cochrane | no estimate extracted | NR | No studies |
Pegloticase every two weeks (biweekly) vs placebo Proportion with complete resolution of tophi · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | RR 5.45 [1.38, 21.54] | 1 study · 79 participants | Moderate |
Monthly pegloticase vs placebo Quality of life ‐ not reported · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Monthly pegloticase vs placebo Serum urate normalisation ‐ not reported · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Monthly pegloticase vs placebo Function ‐ not reported · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Monthly pegloticase vs placebo Number of participant withdrawals due to adverse events · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | RR 8.19 [1.12, 59.71] | 1 study · 127 participants | Moderate |
Monthly pegloticase vs placebo Total adverse events · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | RR 1.05 [0.98, 1.14] | 1 study · 127 participants | Moderate |
Lesinurad 200 mg plus allopurinol vs placebo plus allopurinol Proportion with complete resolution of a target tophus · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | RR 0.4 [0.04, 4.57] | 2 studies · 103 participants | Moderate |
Lesinurad 400 mg plus allopurinol vs placebo plus allopurinol Proportion with complete resolution of a target tophus · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | RR 0.79 [0.42, 1.49] | 2 studies · 98 participants | Moderate |
Lesinurad 400 mg plus febuxostat CONTINUED vs lesinurad 200 mg plus febuxostat CONTINUED Proportion with complete resolution of a target tophus · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | RR 1.11 [0.85, 1.46] | 1 study · 129 participants | Low |
Lesinurad 400 mg plus febuxostat CONTINUED vs lesinurad 200 mg plus febuxostat CONTINUED Total adverse events · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | RR 1.12 [0.96, 1.32] | 1 study · 129 participants | Low |
Lesinurad 400 mg plus febuxostat CONTINUED vs lesinurad 200 mg plus febuxostat CONTINUED Number of participant withdrawals due to adverse events · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | RR 0.98 [0.44, 2.2] | 1 study · 129 participants | Low |
Pegloticase every two weeks (biweekly) vs placebo Joint pain reduction ‐ not reported · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Lesinurad 400 mg plus febuxostat CONTINUED vs lesinurad 200 mg plus febuxostat CONTINUED Mean sUA at end of 12 months · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | no estimate extracted | 1 study · 129 participants | Low |
Lesinurad 400 mg plus febuxostat CROSS vs lesinurad 200 mg plus febuxostat CROSS Proportion with complete resolution of a target tophus · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | RR 1.18 [0.7, 1.98] | 1 study · 67 participants | Low |
Lesinurad 400 mg plus febuxostat CROSS vs lesinurad 200 mg plus febuxostat CROSS Total adverse events · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | RR 1.19 [1, 1.41] | 1 study · 67 participants | Low |
Lesinurad 400 mg plus febuxostat CROSS vs lesinurad 200 mg plus febuxostat CROSS Number of participant withdrawals due to adverse events · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | RR 2.43 [0.51, 11.64] | 1 study · 67 participants | Low |
Lesinurad 400 mg plus febuxostat CROSS vs lesinurad 200 mg plus febuxostat CROSS Mean sUA at end of 12 months · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | no estimate extracted | 1 study · 67 participants | Low |
Pegloticase every two weeks (biweekly) vs placebo Quality of life ‐ not reported · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Pegloticase every two weeks (biweekly) vs placebo Serum urate normalisation ‐ not reported · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Pegloticase every two weeks (biweekly) vs placebo Function ‐ not reported · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Pegloticase every two weeks (biweekly) vs placebo Number of participant withdrawals due to adverse events · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | RR 7.59 [1.04, 55.55] | 1 study · 128 participants | Moderate |
Pegloticase every two weeks (biweekly) vs placebo Total adverse events · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | RR 0.99 [0.91, 1.07] | 1 study · 128 participants | Moderate |
Monthly pegloticase vs placebo Proportion with complete resolution of tophi · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | RR 2.86 [0.68, 11.97] | 1 study · 79 participants | Moderate |
Monthly pegloticase vs placebo Joint pain reduction ‐ not reported · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | no estimate extracted | NR | No studies |
NSAIDs vs placebo Pain: ≥ 50% improvement in pain (spontaneous pain at 24 hours) · acute gout Non‐steroidal anti‐inflammatory drugs for acute gout (2021) · Cochrane | RR 2.75 [1.13, 6.72] | NR | Low |
Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors Function: mean change in pain with movement from baseline on4‐point (0 to 3, 0 best function) Likert scale · acute gout Non‐steroidal anti‐inflammatory drugs for acute gout (2021) · Cochrane | no estimate extracted | NR | Low |
Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors Participants' global assessment of treatment successon 5‐point (0 very good) Likert scale · acute gout Non‐steroidal anti‐inflammatory drugs for acute gout (2021) · Cochrane | no estimate extracted | NR | Moderate |
Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors Health‐related quality of life on SF‐36 (mental health component)Scale from 0 to 100 (0 worst quality of life) · acute gout Non‐steroidal anti‐inflammatory drugs for acute gout (2021) · Cochrane | no estimate extracted | NR | Low |
Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors Withdrawals due to adverse events · acute gout Non‐steroidal anti‐inflammatory drugs for acute gout (2021) · Cochrane | RR 2.34 [1.33, 4.14] | NR | Moderate |
Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors Total adverse events · acute gout Non‐steroidal anti‐inflammatory drugs for acute gout (2021) · Cochrane | RR 1.94 [1.36, 2.78] | NR | Moderate |
NSAIDs vs glucocorticoids Pain: mean decrease per hour on a VAS scale (0 to 100, 0 no pain) · acute gout Non‐steroidal anti‐inflammatory drugs for acute gout (2021) · Cochrane | no estimate extracted | NR | Moderate |
NSAIDs vs glucocorticoids Inflammation: swelling mean difference in change from baseline to 14 days · acute gout Non‐steroidal anti‐inflammatory drugs for acute gout (2021) · Cochrane | no estimate extracted | NR | Low |
NSAIDs vs glucocorticoids Function: walking disability during first 6 hours · acute gout Non‐steroidal anti‐inflammatory drugs for acute gout (2021) · Cochrane | no estimate extracted | NR | Moderate |
NSAIDs vs glucocorticoids Patients' global assessment of treatment success at day 3 to 4 · acute gout Non‐steroidal anti‐inflammatory drugs for acute gout (2021) · Cochrane | RR 0.92 [0.7, 1.22] | NR | Moderate |
NSAIDs vs glucocorticoids Health‐related quality of life (HRQoL)Not reported · acute gout Non‐steroidal anti‐inflammatory drugs for acute gout (2021) · Cochrane | no estimate extracted | NR | No studies |
NSAIDs vs placebo Inflammation: swelling · acute gout Non‐steroidal anti‐inflammatory drugs for acute gout (2021) · Cochrane | RR 1.08 [0.79, 1.49] | NR | Low |
NSAIDs vs glucocorticoids Withdrawals due to adverse events · acute gout Non‐steroidal anti‐inflammatory drugs for acute gout (2021) · Cochrane | RR 2.8 [0.55, 14.22] | NR | Moderate |
NSAIDs vs glucocorticoids Total adverse events · acute gout Non‐steroidal anti‐inflammatory drugs for acute gout (2021) · Cochrane | RR 1.62 [1.03, 2.55] | NR | Moderate |
NSAIDs vs placebo Function: ≥ 50% improvement in pain with movement at 24 hours · acute gout Non‐steroidal anti‐inflammatory drugs for acute gout (2021) · Cochrane | RR 4 [0.5, 31.74] | NR | Low |
NSAIDs vs placebo Participants' global assessment of treatment: not measured№. of participants: 30 (1 RCT) · acute gout Non‐steroidal anti‐inflammatory drugs for acute gout (2021) · Cochrane | no estimate extracted | NR | Low |
NSAIDs vs placebo Health‐related quality of life: not measured№. of participants: 30 (1 RCT) · acute gout Non‐steroidal anti‐inflammatory drugs for acute gout (2021) · Cochrane | no estimate extracted | NR | Low |